Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Mar;14(3):838-41.
doi: 10.1093/humrep/14.3.838.

Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study

B Jablonowska  1 , A Selbing, M Palfi, J Ernerudh, S Kjellberg, B Lindton
Affiliations
Clinical Trial

Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study

B Jablonowska et al. Hum Reprod. 1999 Mar.

Abstract

The aim of this study was to evaluate the therapeutic efficacy of intravenous immunoglobulin (IVIG) in the prevention of recurrent spontaneous abortion (RSA). In a double-blind, randomized, placebo-controlled study, 41 women with a history of unexplained recurrent spontaneous abortion were treated with IVIG or saline infusions during pregnancy. The birth of a child was considered a successful outcome. The overall success rate was 77% in the IVIG group compared with 79% in the placebo group. For women with primary RSA the success rates were 82 (IVIG) and 89% (placebo), and for women with secondary RSA the rates were 73 (IVIG) and 70% (placebo). We found no statistically significant difference in treatment results between IVIG and placebo.

PubMed Disclaimer

Publication types

LinkOut - more resources